Cited by Predictive Factors for Primary and Secondary Nonresponders to Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Study

The Association of Inflammatory Indexes Derived from Peripheral Blood Cell Count and Clinical Signs with Response to Treatment with Dupilumab in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis DOI

Lingzhao Zhang,

Jiangshan Pi,

Jinsong Wang

et al.

Journal of Inflammation Research, Journal Year: 2025, Volume and Issue: Volume 18, P. 271 - 282

Published: Jan. 1, 2025

Dupilumab is a safe and effective treatment for moderate to severe atopic dermatitis (AD), but real-world data in pediatric patients China are limited. Currently, there no exploration of changes blood cell counts derived indexes patients, especially under 6 years old. To investigate the before after dupilumab Chinese children with AD, relationship clinical scores, potential role these on efficacy. We conducted retrospective study 109 AD treated dupilumab. Derived inflammatory indexes, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR), eosinophil-to-lymphocyte (ELR), eosinophil-to-neutrophil Ratio (ENR), monocyte-to-lymphocyte (MLR), inflammation response index (SIRI), systemic (SII), aggregate (AISI) were calculated. The correlation between scores at different time points analyzed. Logistic regression ROC curve was employed explore factors associated Baseline ELR ENR positively correlated baseline Eczema Area Severity Index (EASI) Scoring Atopic Dermatitis (SCORAD). Additionally, levels showed positive Peak Pruritus Numeric Rating Scale (PP-NRS). At 4 16 weeks treatment, percentage reduction significantly EASI PP-NRS. results indicated that high could predict poor treatment. disease severity score during act as predictor efficacy age.

Language: Английский

Citations

Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study DOI

Luciano Ibba,

Costanza Falcidia,

S. Di Giulio

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(9), P. 2953 - 2953

Published: April 24, 2025

Background: Atopic dermatitis (AD) is a chronic pruritic inflammatory disease affecting children and adults. Upadacitinib abrocitinib are selective Janus kinase 1 inhibitors approved for the treatment of moderate-to-severe AD. Although their efficacy safety described in phase 3 clinical trials, real-world data limited. Objectives: We aimed to evaluate effectiveness upadacitinib real-life adult population with AD throughout an extended observation period. Methods: This retrospective observational study was conducted by analyzing from electronic records IRCCS Humanitas Research Hospital January 2023 December 2024. Patients were administered either (15 or 30 mg) (100 200 mg). Effectiveness evaluated using clinician-reported scores (Investigator Global Assessment [IGA] Eczema Area Severity Index [EASI]) patient-reported outcomes (peak pruritus numerical rating scale [PP-NRS]) at weeks 8, 16, 32 52. Statistical significance set probability value (p-value) < 0.05. Adverse events also collected. Results: In total, 129 patients included study, 84 them reached 52 weeks. At week 52, EASI 75, 90, 100 responses 88.9%, 70.8%, 54.2% upadacitinib, 100%, 91.7%, 75% abrocitinib. An IGA score equal 0 achieved 84.7% treated 100% those receiving A four-point reduction baseline PP-NRS reported 86.1% 83.3% after one year follow-up. Conclusions: Our showed comparable even higher terms compared phase-3 no new concerns, supporting

Language: Английский

Citations

Identification of Early and Late Responders to Anti-IL-13 Antibody Tralokinumab in Atopic Dermatitis: A Real-World Japanese Study DOI

Teppei Hagino, Hidehisa Saeki,

Eita Fujimoto

et al.

Dermatitis, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 27, 2024

Abstract: Background: Tralokinumab, an anti-IL-13 antibody, is effective treatment for patients with atopic dermatitis (AD). However, predictive factors responders to tralokinumab remain unclear in real-world practice.

Language: Английский

Citations

Predictive Factors for Primary and Secondary Nonresponders to Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Study DOI

Teppei Hagino, Hidehisa Saeki,

Eita Fujimoto

et al.

Dermatitis, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 5, 2024

Some patients with atopic dermatitis (AD) do not sufficiently respond to upadacitinib, a Janus kinase 1 inhibitor. However, predictive factors for nonresponders remain unclear in real-world practice.

Language: Английский

Citations